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3D coordinates (pbd file) of model of 7 bound to the hP2Y6R See separate file Video of molecular dynamics simulation (avi file) of 7 bound to the hP2Y6R (run 3) See separate file 0.04 mmol) were added to a solution of N 4 -benzyloxycytidine (12 mg, 0.034 mmol) in DMF (1.0 mL). The mixture was stirred for 2 d at room temperature under a nitrogen atmosphere. Solvent was evaporated and the residue was purified to isolate MRS4166 as triethylammonium salt (5 mg, 0.007 mmol, 20% yield). Purification was done using HPLC with a Luna 5 μmRP-C18 semipreparative column (250 mm x 10.0 mm) using flow rate of 4 mL/min; 10 mM triethylammonium acetate (TEAA)-CH3CN from 80:20 to 60:40 in 20 mins (Rt ~ 14 min). Analytical purity was tested using Zorbax SB-Aq 5 μm analytical column (50mm x 4.6mm), the mobile phase was a isocratic solvent system of 5 mM TBAP : CH3CN 80:20 (Rt ~ 10 min) and the flow rate was 1 mL/ min, purity >98%. 1 (S)-methanocarba-uridine-5-,β-methylenediphosphate triethylammonium salt (15) : Compound 27 (5.0 mg, 0.02 mmol) and proton sponge (8.4 mg, 0.039 mmol) were taken in a round bottom flask and dried under high vacuum for 1 h. To this under inert atmosphere was added trimethylphosphate (0.6 mL). The reaction mixture was stirred at rt for 15 min and then cooled to 0 °C with ice-bath. Bisphosphonic acid dichloride (10 mg, 0.039 mmol) was added at once and stirring continued for 1 h. A cold triethylammonium bicarbonate solution (0.3M, 1 mL) was added and the mixture stirred at rt for 30 min. The contents of the flask were frozen and subjected to lyophilization. The residue was dissolved in water, purified first by ion-exchange chromatography and then by RP-HPLC to afford pure product 15 as white solid (2.08 mg, 17%; IE-LPLC Rt = 17.3 min; RP-HPLC acetonitrile/10 mM triethylammonium acetate 0/100 to 10/90 in 40 min @5 mL/min, Rt = 27.9 min). 1 Compound 30 (5.0 mg, 0.018 mmol) and proton sponge (7.6 mg, 0.036 mmol) were taken in a round bottom flask and dried under high vacuum for 1 h. To this under inert atmosphere was added trimethylphosphate (0.6 mL). The reaction mixture was stirred at rt for 15 min and then cooled to 0 °C with ice-bath. Bisphosphonic acid dichloride (8.8 mg, 0.036 mmol) was added at once and stirring continued for 1 h. A cold triethylammonium bicarbonate solution (0.3M, 1 mL) was added and the mixture stirred at rt for 30 min. The contents of the flask were frozen and subjected to lyophilization. The residue was dissolved in water, purified first by ion-exchange chromatography and then by RP-HPLC to afford pure product 16 as a white solid (1.46 OMe-(S)-methanocarba-CDP; 18): Method -A: To compound 30 (vacuum dried, 10 mg, 0.035 mmol) was added trimethylphosphate (0.2 mL) and proton-sponge (15 mg, 0.071 mmol), and the mixture stirred for 15 min. The mixture was cooled to 0°C and was added POCl3 (6.5 µL, 0.071 mmol). After stirred at 0 °C for 2 h, was added 0.5M tributylammonium phosphate (0.7 mL, 0.35 mmol) and the mixture stirred for 10 min. 0.3M triethylammonium bicarbonate (2 mL) was added and the mixture stirred at room temperature for 1 h. The reaction mixture was lyophilized and the residue was purified first by ion-exchange chromatography and later by RP-HPLC to afford 18 as a white solid (10.22 To a compound 38 (lyophilized, 30.0 mg, 0.065 mmol) was added anhydrous DMF (0.2 mL), tributylamine (16 µL, 0.065 mmol) and 4Å molecular sieves and the mixture stirred for 1 h. The reaction mixture was cooled to 0 °C and added compound 39 (33.0 mg, 0.085 mmol) with vigorous stirring. After 10 min, 0.5M tributylammonium phosphate (650 µL, 0.032 mmol, See Note-1) and MgCl2 (7.0 mg, 0.065 mmol) was added sequentially, and the mixture stirred at rt for 2 h. Water was added to quench the reaction, the contents frozen and lyophilized. The residue was purified first by ion-exchange chromatography and later by RP-HPLC to afford 18 as a white solid (10.22 + for C11H14N2O5 calculated 255.0981, found 255.0983.
H NMR (400 MHz
In a glass pressure tube, compound 26 (100 mg, 0.173 mmol), 1:1 mixture of dioxane-ethanol (10 mL) and 28% aq. ammonium hydroxide (5 mL) were added sequentially. The pressure tube was sealed and heated to 110 °C for 18 h. The volatile materials were evaporated under vacuum and the residue purified by silica-gel column chromatography to afford 28 as a white foamy solid (80 mg, 87%, Rf = 0.3, TLC eluent = 50% ethyl acetate in hexanes). + for C30H36N2O5Si calculated 555.2291 found 555.2294. To a solution of compound 27 (10 mg, 0.039 mmol) in pyridine (0.5 mL) at 0 °C was added acetic anhydride (0.1 mL) and the mixture stirred at rt for 18 h. Solvent was evaporated under vacuum and the residue purified by silica-gel column chromatography to afford 32 as a colorless waxy solid (11 mg, 74%, Rf = 0.45, TLC eluent = 5% methanol in dichloromethane). After stirring the mixture at 85 °C for 3 h, the contents were cooled and the solvent evaporated. The residue was subjected to silica-gel column chromatography to afford pure product 33 as a white foamy solid (35 mg, 85%, Rf = 0.60, TLC eluent = ethyl acetate). Method A: To a solution of compound 27 (10 mg, 0.04 mmol) in dioxane (0.5 mL) was added iodine (20 mg, 0.08 mmol) and 1N aq. HNO3 (40 µL). The mixture was stirred at 100 °C for 1h, cooled and neutralized by adding dilute aq. NaHCO3. The volatiles were evaporated under high vacuum. The residue was suspended in 1:1 methanol-dichloromethane, filtered and the filtrate evaporated. The crude product was purified by silica-gel column chromatography to afford 34 as -S8 -a white solid, which was further purified by RP-HPLC (3 mg, 20%, Rf = 0.25, TLC eluent = 10% methanol in dichloromethane; RP-HPLC, linear gradient of 0-30% acetonitrile/10 mM TEAB @ 5 mL/min, retention time (Rt) = 36 min). 1 + for C11H13N2O5I calculated 380.9947, found 380.9940. Method B: Compound 33 (11 mg, 0.022 mmol) was treated with 7N ammonia in methanol (0.5 mL) and the mixture stirred at rt for 18 h. The solvent was evaporated under vacuum and the residue purified by silica-gel chromatography to afford 34 as a white solid (5 mg, 60%). (14), 5298-5311. [1] [2] [3] [4] [5] Potencies are presented in the form of EC50 values, which represent the concentration of agonist at which 50% of the maximal effect is achieved. These values were determined using a four-parameter logistic equation and the GraphPad software package (GraphPad, San Diego, CA). The results are presented as mean ± standard error and are the average of three to six different experiments with each molecule.
b EC50 values at the P2Y14 receptor were determined for only a few cases: 1, 0.160 µM; 8, 3.32 µM; 13, inactive at 10 µM; 52, 0.011 µM.
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Molecular Modeling Methods
Protein preparation. A previously published 1 CXCR4-based homology model of the hP2Y6R in complex with a fluorescent probe (compound 16 in ref. 1) was prepared with the Protein Preparation Wizard tool implemented in the Schrödinger suite 2 by adding missing protein side chains and optimizing hydrogen atoms (OPLS3 force field, 0.30 Å convergence criterion for heavy atoms RMSD). The protonation states of histidine residues were determined according to H-bond patterns with surrounding residues as follows: His111/136/188 and His91/130/256 were protonated on the N δ and the N ε , respectively.
Docking. The structure of the ribose dinucleotide derivative 7 was built and prepared for docking using the Builder tool implemented in the Schrödinger suite and minimized using the OPLS3 force field. Molecular docking was performed with Glide 3 , by centering the grid on the barycenter of the fluorescent probe (compound 16 in ref. 1) upon removal of the tethered fluorophore group and by using an inner box of 10 x 10 x 10 Å and an outer box extended by 26 Å in each direction from the inner box to cover the whole extracellular portion of the receptor. Docking was performed considering the protein binding sites residues rigid by using the standard precision (SP) scoring function (10 poses). After visual inspection of the docking poses, the highest ranked pose was selected as starting conformation for subsequent MD simulations.
Molecular Dynamics. MD system setup, equilibration, and production were performed with the HTMD 4 module (Acellera, Barcelona Spain, version 1.5.5). The ligand-protein complexes were embedded into an 80 x 80 Å 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) membrane leaflet generated through the VMD Membrane Plugin tool 5 . Overlapping lipids (within 0.6 Å) were removed upon protein insertion and the systems were solvated with TIP3P 6 water and neutralized by Na + /Cl -counter-ions (final concentration 0.154 M). MD simulations with periodic boundaries conditions were carried out with ACEMD (Acellera, version 2016.10.27) 7 using the CHARMM36 8,9 /CGenFF(3.0.1) 10,11 force fields for lipid and protein, and ligand atoms, respectively. Ligand parameters were retrieved from the ParamChem service (https://cgenff.paramchem.org, accessed 07/2017, version 1.0.0) with no further optimization. The systems was equilibrated through a 5000-step minimization followed by 40 ns of MD simulation in the NPT ensemble by applying initial constrains (0.8 for the ligand atoms, 0.85 for alpha carbon atoms, and 0.4 for the other protein atoms) that were linearly reduced after 20 ns. During the equilibration procedure, the temperature was maintained at 310 K using a Langevin thermostat with a low damping constant of 1 ps -1 , and the pressure was maintained at 1 atm using a Berendensen barostat. Bond lengths involving hydrogen atoms were constrained using the M-SHAKE 12 algorithm. The equilibrated system was subjected to 100 ns of unrestrained MD simulation run in triplicate (NVT ensemble, timestep = 2 fs, damping constant = 0.1 ps -1 ). Longrange Coulomb interactions were handled using the particle mesh Ewald summation method (PME) 13 with grid size rounded to the approximate integer value of cell wall dimensions. A nonbonded cutoff distance of 9 Å with a switching distance of 7.5 Å was used. All simulations were run on a NVIDIA GeForce GTX 1080.
MD Trajectory Analysis. MD trajectory analysis was performed with an in-house script exploiting the NAMD 2.10 14 mdenergy function and the RMSD trajectory tool (RSMDTT) implemented in VMD 5 . Selection of a representative trajectory was based upon the total ligandprotein interaction energy (IEtot) expressed as the sum of van der Waals (IEvdW) and electrostatic -S14 -(IEele) contribution as previously described 15 . Analysis of ribose pseudorotation phase angle (P) 16 was performed with an in house tcl script, by using the following equation and the standard definition of ribose dihedral angles υ0-υ4: Figure S1 . A) Superimposition of the hP2Y1R-based (cyan ribbons) and the CXCR4-based (magenta ribbons) homology models of the hP2Y6R. The displacement of the downstream portion of the ECL2 is highlighted with an arrow and the region where the two vicinal Pro residues are located is circled in red. The N-Term domain is omitted to aid visualization. The hP2Y1R-based model was built with Prime 3.7 (energy-based model, ClustalW sequence alignment manually refined) by retaining the ligand co-crystallized with the template (MRS2500) and subjecting the resulting complex to Monte Carlo refinement (Refined residues: 1-22, 268-275; Force Field: OPLS2005; solvation model: VSGB;10 output structures generated). B) Manually refined sequence alignment of the hP2Y1R X-ray template (PDB ID: 4XNW) and the target hP2Y6R (UniProt ID: Q15077). The non-conserved Pro-Pro motif in ECL2 is highlighted in red.
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